Biotech: Page 14
-
Q&A // Biotech Spotlight
While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer
The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.
By Karissa Waddick • March 9, 2023 -
Podcast
Woman of the Week: Lucy Therapeutics’ Amy Ripka
How a 3.2-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.
By Taren Grom • March 8, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Targeting the new ‘Golden Girls’
With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.
By Taren Grom • March 8, 2023 -
3 keys to good storytelling in pharma
The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.
By Alexandra Pecci • March 7, 2023 -
Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?
The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?
By Michael Gibney • March 7, 2023 -
FDA ups generics and biosimilar approvals for a shot at lower drug costs
As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022.
By Karissa Waddick • March 6, 2023 -
Why layoffs are not the answer to biopharma’s troubled market
As companies look to cut costs, an EY analyst urges them to consider not cutting staff.
By Kelly Bilodeau • March 6, 2023 -
PharmaVoice 100 honorees: Where are they now?
How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles.
By Taren Grom , Karissa Waddick • March 3, 2023 -
Q&A // Biotech Spotlight
Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology
With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.
By Taren Grom • March 2, 2023 -
Q&A // First 90 Days
The ‘recovering academic’ leading Allogene to the next stage of cell therapy
Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.
By Michael Gibney • March 2, 2023 -
Podcast
Woman of the Week: Denali Therapeutics’ Cindy Dunkle
As chief people officer, Dunkle is harnessing the company’s unique culture to foster innovation.
By Taren Grom • March 1, 2023 -
Do R&D costs justify the price of drugs? Nope, new study says
A BMJ study found that spending on drug sales vastly outstripped spending on drug development.
By Alexandra Pecci • March 1, 2023 -
Multimillion-dollar therapies are changing how payers foot the bill
With more gene therapies headed to market, novel payment methods are emerging from regulators and academia.
By Meagan Parrish • Feb. 28, 2023 -
Reata’s stock plummets amid sudden FDA neuro office shakeup
The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.
By Karissa Waddick • Feb. 28, 2023 -
Who is Vivek Ramaswamy — the biotech entrepreneur turned presidential candidate?
The former CEO of Roivant, who became the face of the “anti-woke” business movement, is now running for the 2024 Republican presidential nomination. Here’s what he stands for.
By Karissa Waddick • Feb. 27, 2023 -
As clinical trials face a hiring crunch, here’s how research organizations can pivot
Staffing shortages are causing inefficiencies in clinical trials, but one leading CRO is finding ways to adapt.
By Kelly Bilodeau • Feb. 27, 2023 -
Q&A // Biotech Spotlight
Cytokinetics looks to muscle into the cardiovascular market
With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.
By Taren Grom • Feb. 24, 2023 -
Profile
Tapping into the molecular fountain of youth
Kristen Fortney, CEO of BioAge Labs, wants to improve the human life span by focusing on the human health span.
By Alexandra Pecci • Feb. 22, 2023 -
Podcast
Woman of the Week: Alltrna’s Michelle Werner
The first-time CEO has her sights on addressing thousands of diseases with the company’s tRNA platform.
By Taren Grom • Feb. 22, 2023 -
Biotechs teeter on unsteady ground in 2023 and some may close shop
A slew of early stage biotechs were forced to shut down last year as the market tanked. Will the trend continue?
By Kelly Bilodeau • Feb. 21, 2023 -
Despite rare disease market growth, pharma leaders see development obstacles ahead
Investment in rare disease research is increasing, but a recent poll of PharmaVoice readers found that roadblocks remain.
By Karissa Waddick • Feb. 17, 2023 -
Q&A // First 90 Days
Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies
Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.
By Taren Grom • Feb. 17, 2023 -
Marking one year as FDA commissioner, Califf lays out vision for agency’s future
Califf outlined hopes to address advisory committees, drug pricing, digital health and more.
By Karissa Waddick • Feb. 16, 2023 -
Q&A // Biotech Spotlight
Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm
The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.
By Michael Gibney • Feb. 16, 2023 -
Q&A
Managing for resilience: Passage’s ups and downs in gene therapy
After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.
By Meagan Parrish • Feb. 15, 2023